These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21393329)

  • 1. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.
    Wood JC; Glynos T; Thompson A; Giardina P; Harmatz P; Kang BP; Paley C; Coates TD
    Haematologica; 2011 Jul; 96(7):1055-8. PubMed ID: 21393329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.
    Wood JC; Kang BP; Thompson A; Giardina P; Harmatz P; Glynos T; Paley C; Coates TD
    Blood; 2010 Jul; 116(4):537-43. PubMed ID: 20421452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
    Cassinerio E; Roghi A; Orofino N; Pedrotti P; Zanaboni L; Poggiali E; Giuditta M; Consonni D; Cappellini MD
    Ann Hematol; 2015 Jun; 94(6):939-45. PubMed ID: 25563596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK
    Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
    Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
    Haematologica; 2011 Jan; 96(1):48-54. PubMed ID: 21071497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
    Pathare A; Taher A; Daar S
    Ann Hematol; 2010 Apr; 89(4):405-9. PubMed ID: 19798501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R; Ahmed J; Krishnan P; Jankharia B
    Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
    Pennell DJ; Porter JB; Cappellini MD; El-Beshlawy A; Chan LL; Aydinok Y; Elalfy MS; Sutcharitchan P; Li CK; Ibrahim H; Viprakasit V; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
    Blood; 2010 Mar; 115(12):2364-71. PubMed ID: 19996412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
    Unal S; Hazirolan T; Eldem G; Gumruk F
    Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
    Voskaridou E; Plata E; Douskou M; Sioni A; Mpoutou E; Christoulas D; Dimopoulou M; Terpos E
    Ann Hematol; 2011 Jan; 90(1):11-5. PubMed ID: 20661572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
    Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
    Daar S; Pathare A; Nick H; Kriemler-Krahn U; Hmissi A; Habr D; Taher A
    Eur J Haematol; 2009 Jun; 82(6):454-7. PubMed ID: 19191863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
    Fragomeno C; Roccabruna E; D'Ascola DG
    Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China].
    Shi J; Chang H; Zhang L; Shao Y; Nie N; Zhang J; Huang J; Zhang L; Tang X; Quan R; Zheng C; Xiao H; Hu D; Hu L; Liu F; Zhou Y; Zheng Y; Zhang F
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):1-6. PubMed ID: 26876245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bad liver and a broken heart.
    Coates TD
    Blood; 2014 Mar; 123(10):1434-6. PubMed ID: 24627546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring and treatment of iron overload: state of the art and new approaches.
    Porter JB
    Semin Hematol; 2005 Apr; 42(2 Suppl 1):S14-8. PubMed ID: 15846580
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
    Lal A; Porter J; Sweeters N; Ng V; Evans P; Neumayr L; Kurio G; Harmatz P; Vichinsky E
    Blood Cells Mol Dis; 2013 Feb; 50(2):99-104. PubMed ID: 23151373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.